In recent years technology has revolutionized the management of diabetes: the technological approach is based on the use of insulin pumps and sensors for continuous glucose monitoring, and on the possibility to integrate these 2 systems to create a device capable of autonomously modifying the administration of insulin according to the values ​​detected by the sensor, thus creating the so-called artificial pancreas or closed-loop system. This evidence concerns the gene INS and diabetes mellitus.